Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Allogeneic transplantation in Cutaneous T-cell Lymphoma: improved outcomes associated with early transplantation and acute graft versus host disease

Bone Marrow Transplantation volume 57, pages 1332–1334 (2022)Cite this article

Subjects

Cutaneous T-cell lymphoma (CTCL) including mycosis fungoides (MF) and Sézary syndrome (SS) is a rare [1], usually indolent disease, however patients with transformed MF (tMF) and Sézary Syndrome (SS) have a median survival of less than five years [2]. Chemotherapy results in short term disease control, however a number of novel agents are showing promise in improving outcomes including brentuximab vedotin (BV) in CD30+ve MF and mogamulizumab in both MF and SS [3,4,5] and treatment pathways incorporating their use with bexarotene and extracorporeal photopheresis are being developed.

Allogeneic stem cell transplantation (allo-SCT) remains the only curative treatment for CTCL, though outcomes are adversely affected by a significant infection-related treatment-related mortality (TRM) and high relapse rate [6]. Early referral to a multi-disciplinary transplant team with appropriate expertise is key to optimising bridging treatment, timing of transplant and conditioning approaches [7]. We report results from a retrospective analysis of CTCL patients undergoing allo-SCT over a 10-year period at a national transplant centre to examine the efficacy and toxicity of allo-SCT in advanced CTCL.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Survival outcomes for patients undergoing allo-SCT for CTCL.

Data availability

All material described in this manuscript, including all relevant raw data, will be freely available to any researcher wishing to use them for non-commercial purposes, without breaching patient confidentiality.

References

  1. Ottevanger R, de Bruin DT, Willemze R, Jansen PM, Bekkenk MW, de Haas ERM, et al. Incidence of mycosis fungoides and sezary syndrome in the Netherlands between 2000 and 2020. Br J Dermatol. 2021;185:430–65.

    Article  Google Scholar 

  2. Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and sézary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18:5051–60.

    Article  CAS  Google Scholar 

  3. Prince HM, Kim YH, Horwitz S, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390:555–66.

    Article  CAS  Google Scholar 

  4. Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1192–204.

    Article  CAS  Google Scholar 

  5. Hughes CFM, Khot A, Mccormack C, Lade S, Westerman DA, Twigger R, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood. 2015;125:71–81.

    Article  CAS  Google Scholar 

  6. Mori T, Shiratori S, Suzumiya J, Kurokawa M, Shindo M, Naoyuki U, et al. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome. Hematological Oncol. 2020;38:266–71.

    Article  CAS  Google Scholar 

  7. Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, et al. Primary cutaneous lymphomas, version 2.2020. Featured updates to the NCCN guidelines. JNCCN J Natl Compr Cancer Netw. 2020;18:522–36.

    Article  Google Scholar 

  8. Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: A retrospective analysis of the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2010;28:4492–9.

    Article  Google Scholar 

  9. Domingo-Domenech E, Duarte RF, Boumedil A, Onida F, Gabriel I, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2021;56:1391–401.

    Article  CAS  Google Scholar 

  10. Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014;49:1360–5.

    Article  CAS  Google Scholar 

  11. Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005;353:1321–31.

    Article  CAS  Google Scholar 

  12. Herbert KE, Spencer A, Grigg A, Ryan G, McCormack C, Prince HM. Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34:521–5.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, St. James’s Hospital, Dublin 8, Ireland

    Daniel Angelov, James Dillon, Emily Pender, Larry Bacon, Greg Lee, Liz Higgins & Elisabeth Vandenberghe

  2. Department of Histopathology, St. James’s Hospital, Dublin 8, Ireland

    Lisa Mellerick, Niamh Leonard & Máirín McMenamin

  3. Northern Ireland Cancer Centre, Belfast, United Kingdom

    Heather McCarty

  4. Department of Radiation Oncology, St James’s Hospital, Dublin 8, Ireland

    Charles Gillham

  5. Department of Haematology, Beaumont Hospital, Dublin 9, Ireland

    John Quinn

  6. Department of Dermatology, St. James’s Hospital, Dublin 8, Ireland

    Susan O’Gorman

Authors
  1. Daniel Angelov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Dillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lisa Mellerick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emily Pender
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Larry Bacon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Greg Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Liz Higgins
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Heather McCarty
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Charles Gillham
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. John Quinn
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Susan O’Gorman
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Niamh Leonard
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Máirín McMenamin
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Elisabeth Vandenberghe
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

EV conceived the research project; DA and EV wrote the paper; DA, EP, JD and LM extracted the data; DA analysed and interpreted the data and created all tables and graphs; All authors contributed to the writing and final review of the paper.

Corresponding author

Correspondence to Daniel Angelov.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Angelov, D., Dillon, J., Mellerick, L. et al. Allogeneic transplantation in Cutaneous T-cell Lymphoma: improved outcomes associated with early transplantation and acute graft versus host disease. Bone Marrow Transplant 57, 1332–1334 (2022). https://doi.org/10.1038/s41409-022-01713-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-022-01713-7

This article is cited by

Search

Advanced search

Quick links